Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults
NCT03181074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2020-03-18
Summary
This early post-marketing study is an observational, prospective and descriptive study of patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico.
Conditions
- Hepatitis C
Interventions
- OTHER
-
Non-Interventional
Non-Interventional
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-10-21
- Primary Completion
- 2019-08-19
- Completion
- 2019-08-19
Countries
- Mexico
Study Locations
More Related Trials
-
A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3
NCT02551861 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
NCT01628692 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
NCT02496078 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants
NCT02268864 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
NCT02673489 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period
NCT02531269 ·Status: COMPLETED
-
Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients
NCT01797848 ·Status: WITHDRAWN ·Phase: PHASE3
-
Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
NCT02118012 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
NCT01741545 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
NCT01492426 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
NCT02349048 ·Status: COMPLETED ·Phase: PHASE2
-
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
NCT00663208 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
NCT01718158 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
NCT01257204 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
NCT01125189 ·Status: COMPLETED ·Phase: PHASE2
-
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
NCT02159352 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C
NCT02639585 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
NCT02556086 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of CTS-1027 in Hepatitis C Patients
NCT00570336 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
NCT01616524 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
NCT01842451 ·Status: COMPLETED ·Phase: PHASE2
-
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
NCT02640547 ·Status: COMPLETED
-
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
NCT02161939 ·Status: NO_LONGER_AVAILABLE
-
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
NCT03487848 ·Status: TERMINATED ·Phase: PHASE2
-
Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)
NCT00724451 ·Status: COMPLETED